chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4-year-old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 18-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4-year-old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 18-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested. Sender's Comments: US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517.
Sex: U
Vaccine: HEP
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, drug reactions or allergies, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB lot # L048849, expiry date 04-FEB-2018 (dose and route of administration were not reported). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 27 degrees Fahrenheit for 1 hour and 20 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information is not expected as there was no consent to contact physician. Sender's Comments: US-009507513-1703USA007944.
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, drug reactions or allergies, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9 lot # M031557, expiry date 07-APR-2019; lot # L040054, expiry date 26-DEC-2017 (dose and route of administration were not reported). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 27 degrees Fahrenheit for 1 hour and 20 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information is not expected as there was no consent to contact physician.; Sender's Comments: US-009507513-1703USA007944:
Sex: U
Vaccine: RV5
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, drug reactions or allergies, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of ROTATEQ orally, lot # M018957, expiry date 22-NOV-2017; lot # M014544, expiry date 27-NOV-2017; lot # M004885, expiry date 23-OCT-2017 (dose was not reported). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 27 degrees Fahrenheit for 1 hour and 20 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information is not expected as there was no consent to contact physician.; Sender's Comments:  US-009507513-1703USA007944:
Age: 10.0
Sex: M
Vaccine: TDAP
Symptoms: Contusion, Full blood count
Clinical narrative: Mom called stating pt had bruising and hx of ITP after Dtap vaccine age 4.
Age: 0.17
Sex: M
Vaccine: DTAPHEPBIP, HIBV, PNC13, RV5
Symptoms: Disturbance in social behaviour, Irritability, Pain, Seizure like phenomena, Vomiting
Clinical narrative: Patient received 2 mo vaccines at well-child check on Friday, 4/7. Evening of 4/7 (time unknown patient had a brief seizure-like episode followed by one episode of emesis prompting mother to call paramedics and patient was then taken to ER. Per mother, EMS thought episode (not witnessed by them) consistent with febrile seizure following vaccines. ED evaluation was very reassuring and patient was discharged with instructions for supportive care and to return with worsening. Morning of 4/8/17, patient was acting at baseline per mother. However, evening of 4/8/17, patient was increasingly fussy, acting as if in pain, and not as interactive as normal. Denied fever, further emesis, difficulty breathing, abnormal movements.
Age: 59.0
Sex: F
Vaccine: TDAP
Symptoms: Erythema, Pain, Swelling
Clinical narrative: Noticed swelling and redness and soreness day after shot. Has persisted 5 days.
Age: 1.33
Sex: F
Vaccine: TDAP
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: None.
Age: 1.0
Sex: M
Vaccine: HEPA, MMR, VARCEL
Symptoms: Hypoglycaemia, Hyporesponsive to stimuli
Clinical narrative: Hyporesponsiveness and hypoglycemia.
Age: 1.0
Sex: M
Vaccine: MMR, VARCEL
Symptoms: Erythema, Urticaria
Clinical narrative: REDNESS AND WELTS NEAR INJECTION SITE.
Age: 4.0
Sex: F
Vaccine: DTAPIPV, MMRV
Symptoms: Grip strength decreased, Injected limb mobility decreased, Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: Affected arm was swollen, red and painful; difficult to move arm and grasp objects.
Age: 12.0
Sex: F
Vaccine: HPV4
Symptoms: Dizziness, Flushing
Clinical narrative: Occurred 4-5 min after administration, C/O mild light headedness, Slt flush. Recovered in approximately 5 min after lying down.
Age: 1.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 1 year-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 25-OCT-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 1.08
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 13 month-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 25-OCT-2016, the patient was vaccinated with the first improperly stored dose of  VARIVAX, lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.
Age: 1.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 12 months old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 18-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 66.0
Sex: F
Vaccine: PNC13
Symptoms: Arthralgia, Discomfort, Injection site pain, Mobility decreased, Pain in extremity
Clinical narrative: This is a spontaneous report from a contactable nurse reporting for herself. A 66-year-old female patient received PREVNAR 13, via an unspecified route of administration on 31Aug2016 at single dose in the left arm for immunisation. At the same time she was vaccinated with another vaccine but she did not remember the name of that vaccine. Medical history was none. There were no concomitant medications. On Sep2016 after two and half to three weeks after the vaccination the patient experienced discomfort, general soreness in her arm; severe pain in her left arm and it's just below the elbow and into the joint, couldn't rotate her arm, all with outcome of recovering. On an unspecified date, one or two days after the vaccination,  she experienced  pain at the injection site with outcome of recovering. Therapeutic measures as a result of the events included treatment with Aleve.
Age: 1.25
Sex: M
Vaccine: DTP, HIBV, PNC13
Symptoms: Injection site erythema, Injection site warmth
Clinical narrative: R) band 4cm from med to lat leg-red/warm. L) area 1.5cm in diameter-red/warm. MD visualized red reaction on bilateral legs/thigh at IM site.
Age: 5.0
Sex: U
Vaccine: HEPA
Symptoms: Extra dose administered
Clinical narrative: The patient arrived with a separate vaccination record than what was recording in Immunization Information System. Vaccine records reviewed by another nurse. Needed vaccines were not double checked by administering nurse. Vaccination given and then history recorded in vaccination administration record. It was noticed by a clerical staff member when entered the vaccinations into Immunization Information System that an extra dose of Hepatitis A was given.
Age: 29.0
Sex: U
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: Patient was administered an expired Tdap vaccine. Patient will be contacted upon manufacture recommendations.
Age: 32.0
Sex: U
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: Patient had expired TDaP vaccine administered. Patient will be contacted pending manufacture recommendations.
Age: 24.0
Sex: U
Vaccine: MNQ
Symptoms: Product preparation error
Clinical narrative: Mistakenly gave a patient the diluent for MENVEO without adding it to the powdered vaccine.
Age: 52.0
Sex: F
Vaccine: HEPA
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: 52 y/o adult female patient received pediatric dose of HAVRIX.
Sex: U
Vaccine: PPV
Symptoms: Extra dose administered
Clinical narrative: Patient had previously received PPV23 in the past on 1/14/2007. 50 y/o female w/ DM and HTN. Age of patient at time of event: 50. Type of Event: Extra dose.
Age: 13.0
Sex: U
Vaccine: VARCEL
Symptoms: Extra dose administered
Clinical narrative: Patient received extra dose, 3rd dose, of Varicella. Had previously received doses on 11/26/03 and 4/5/07.
Age: 11.0
Sex: U
Vaccine: HEPA
Symptoms: Extra dose administered
Clinical narrative: Patient was given a 3rd dose on the Hep A vaccine.
Age: 25.0
Sex: F
Vaccine: RAB
Symptoms: Headache, Injection site erythema, Injection site pain, Injection site swelling, Nausea
Clinical narrative: Injection site started out tender after injection. Around 9 pm a small red area surrounded injection site and continued to grow over the next 2-2 1/2 weeks. Area was apple size but elongated. Red, swollen area gradually went away but has continue to be sore and tender to touch. Is not aggravated by activity. Patient also complained of a splitting headache and nausea that first 24-48 hours. No treatment was used for pain, nausea or swelling.
Age: 24.0
Sex: F
Vaccine: HEP
Symptoms: Alanine aminotransferase increased, Exposure to communicable disease, Hepatitis B antibody negative, Hepatitis C test negative, Injury associated with device
Clinical narrative: ALT result 152 discovered during exposure lab testing.
Age: 17.0
Sex: M
Vaccine: HPV9
Symptoms: Extra dose administered, No adverse event
Clinical narrative: GIVEN TWO DOSES OF GARDISIL 9.
Age: 38.0
Sex: F
Vaccine: FLU4, TDAP
Symptoms: Pruritus, Urticaria
Clinical narrative: Felt itchy, then at 9:00 PM noticed hives all over torso. Patient took a zyrtec and symptoms relieved by the next morning of 4/12/2017.
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Concussion, Dizziness, Fall, Head injury, Headache
Clinical narrative: Patient passed out about 5 minutes after receiving the Meningococcal B Vaccine. She was standing at the time and fell backward and hit her head. After coming out of it she had pain in her head and neck as well as dizziness. We stayed in the doctors office for approximately 2 hours while the doctor monitored her vitals. Patient has been dealing with a concussion since that time. Also, the day after the vaccine was given she had a reaction at the injection sight. She had a 3 inch diameter of swollen, hot to the touch and very painful to which she was unable to lift or use her left arm.
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Injected limb mobility decreased, Injection site pain, Injection site swelling, Injection site warmth, Loss of consciousness
Clinical narrative: Patient passed out about 5 minutes after receiving the Meningococcal B Vaccine. She was standing at the time and fell backward and hit her head. After coming out of it she had pain in her head and neck as well as dizziness. We stayed in the doctors office for approximately 2 hours while the doctor monitored her vitals. Patient has been dealing with a concussion since that time. Also, the day after the vaccine was given she had a reaction at the injection sight. She had a 3 inch diameter of swollen, hot to the touch and very painful to which she was unable to lift or use her left arm.
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Loss of personal independence in daily activities, Neck pain, Spinal X-ray normal
Clinical narrative: Patient passed out about 5 minutes after receiving the Meningococcal B Vaccine. She was standing at the time and fell backward and hit her head. After coming out of it she had pain in her head and neck as well as dizziness. We stayed in the doctors office for approximately 2 hours while the doctor monitored her vitals. Patient has been dealing with a concussion since that time. Also, the day after the vaccine was given she had a reaction at the injection sight. She had a 3 inch diameter of swollen, hot to the touch and very painful to which she was unable to lift or use her left arm.
Age: 1.5
Sex: F
Vaccine: MMR
Symptoms: Crying, Lethargy, Pyrexia, Rash generalised
Clinical narrative: 105.7 fever extremely lethargic, went to ER, was released 6 hours later after getting fever down. Her temperament was extremely off for weeks after, crying for hours on end. She then broke out in a rash over her entire body.
Sex: U
Vaccine: VARCEL
Symptoms: Drug administered to patient of inappropriate age, Wrong drug administered
Clinical narrative: MA had order from provider for Zoster vaccine. MA administered incorrect medication. MA retrieved vial for Varicella vaccine and drew up this vaccine. Varicella is what was administered to the patient instead of Zoster. Age of patient at time of event: 60 years.
Age: 1.1
Sex: U
Vaccine: FLU3
Symptoms: Contraindication to vaccination
Clinical narrative: Pt. was to receive Flu Vaccine. After vaccine was administered Pt. mother asked if there was egg product in the flu, because pt. has allergy to egg. Pt. was assessed by a ARNP. Heart rate and pulse were monitored, Pt. was kept in clinic for 20 minutes. Our LPN gave pt. mother instructions for BENADRYL if needed at home. Age of patient at time of event: 1 years 1 months.
Age: 20.0
Sex: M
Vaccine: HEPAB
Symptoms: Extra dose administered
Clinical narrative: Pt requested Hepatitis A and Hepatitis B vaccine. I checked NCIR to determine what was needed but overlooked that he already had his Hep B vaccine and gave TWINRIX vaccine. Hepatitis A - HAVRIX was the vaccine that should have been given.
Age: 0.3
Sex: U
Vaccine: DTAPIPV
Symptoms: Wrong drug administered
Clinical narrative: Pt was given KINRIX instead of DTaP and IPV separately.
Age: 77.0
Sex: U
Vaccine: PNC13
Symptoms: Extra dose administered, Injection site pain
Clinical narrative: Patient at pharmacy stated that she had not received any pneumonia vaccine since the 1990s. According to guidelines, patients over 65 who have not received pneumonia vaccine or those with unknown vaccine history should be administered one dose of PREVNAR 13. PREVNAR 13 was covered by insurance at no cost and administered to patient. The following day, upon logging vaccine into database, it was discovered that patient had previously received PREVNAR 13 from physician one year ago. Patient had soreness at injection site, but reported no other issues. Age of patient at time of event: 77 years. Type of Event: Extra dose.
Age: 0.2
Sex: U
Vaccine: DTAPIPV
Symptoms: Drug administered to patient of inappropriate age
Clinical narrative: KINRIX meant for ages between 4 to 6 years was inadvertently given to an infant. The vaccine was used instead of the commonly used combination which was out of stock, in order to reduce the number of injections of individual vaccines but the age limits were not verified before giving the vaccine. Age of patient at time of event: 2 months.
Age: 1.5
Sex: U
Vaccine: HEPA
Symptoms: Inappropriate schedule of drug administration
Clinical narrative: Patient was given vaccine 21 days to early in error.
Sex: U
Vaccine: HEP
Symptoms: Drug administered to patient of inappropriate age, No adverse event
Clinical narrative: This patient received two doses of the pediatric hepatitis B vaccine within 24 hours. The patient received the first dose shortly after birth and the second upon arrival to the NICU at a second facility in the organization. The MAR from the previous facility was not reviewed thoroughly. No adverse reactions were noted.
Age: 1.0
Sex: U
Vaccine: HIBV
Symptoms: Extra dose administered
Clinical narrative: PREVNAR 13, Hepatitis A, PROQUAD, and ACTHIB were ordered by provider. No PROQUAD was given. ACTHIB was given twice accidently. Dr. informed. Patient's mother informed. No known adverse reactions. Error occurred at Medical Clinic. Age of patient at time of event: 1 years.
Age: 6.0
Sex: U
Vaccine: DTAPIPV, HEPA, MMR, VARCEL
Symptoms: Extra dose administered
Clinical narrative: Pt's hospital immunization record and state registry not verified by administering nurse. State registry verified but did not include most recent vaccinations given (and charted in the pt's immunization record at the hospital). Colleague reported that registry showed no record of vaccinations (however there were, colleague may have entered incorrect search criteria).
Age: 1.5
Sex: U
Vaccine: DTAPIPV
Symptoms: Drug administered to patient of inappropriate age, Extra dose administered, Wrong drug administered
Clinical narrative: An 18 month old patient up to date on her Hep B vaccine but due for both DTaP and IPV was incorrectly given KINRIX. Provider asked nurse what combination vaccines were available and nurse replied KINRIX. Provider did not check box to confirm appropriate age range and ordered KINRIX. Nurse administered KINRIX. Patient should have either gotten PEDIARIX (and an extra dose of Hep B) or 2 separate vaccines. After the error was realized our pharmacist called the company that manufactures KINRIX and confirmed that KINRIX can be counted as appropriate dose of both vaccines for the child and the vaccine schedule can proceed as prior. The child had no adverse reaction. Parents have been notified.
Age: 5.0
Sex: M
Vaccine: DTAPIPV, MMRV
Symptoms: Injection site rash, Pyrexia
Clinical narrative: 1" 3/4" oval rash around site of MMRV with low grade fever.
Age: 7.0
Sex: U
Vaccine: DTAPHEPBIP
Symptoms: Extra dose administered, Wrong drug administered
Clinical narrative: Patient given DTaP/Polio/Hep B. Patient was due for TDaP at age 7 in addition to the Hep B and Polio. Age of patient at time of event: 7 years 3 months.
Age: 1.0
Sex: F
Vaccine: HEPA, PNC13, VARCEL, VARZOS
Symptoms: No adverse event, Wrong drug administered
Clinical narrative: This spontaneous report as received from a physician refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 22-MAR-2017, the patient was vaccinated with a dose of VARIVAX (dose, route of administration, lot # and expiration date were not reported). On the same day, the patient was also concomitantly vaccinated with a dose of ZOSTAVAX (dose, route of administration, lot # and expiration date were not reported) instead of receiving M-M-R II. No adverse effects were reported. The physician reported that the medical assistant who administered the vaccines did not confuse ZOSTAVAX with M-M-R II, but inadvertently selected the incorrect vaccine from the supply and did not double-check before administration. No dose of M-M-R II was administered. Additional information has been requested.
Sex: U
Vaccine: MMRV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from a Licensed Practical Nurse referring to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of PROQUAD lot # M041082 with expiration date of 04-APR-2018 and lot # M042500 with expiration date of 17-APR-2018 (dose and route of administration were not reported) for prophylaxis. It was also reported that the sterile diluent lot # M014698 with expiration date of 21-NOV-2018 was improperly stored too. There was no adverse effect reported. Administered doses of vaccines and sterile diluent experienced temperature of excursion of 15 degrees Fahrenheit to 46 degrees Fahrenheit (22 degrees Fahrenheit) for 19 hours 30 minutes. Data logger was involved. There were no previous excursions reported. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: No adverse event, Wrong drug administered
Clinical narrative: Information had been received on 29-MAR-2017 from a medical assistant who reported that an unspecified infant patient (age and gender not reported) was inadvertently administered a dose of ZOSTAVAX vial 19400 PFU (dosage, route of administration and lot#/expiration not reported) with diluent instead of an intended dose of VARIVAX on an unknown date. No adverse effect reported. Medical assistant declined to participate in AE intake, therefore most required AE fields are "Refused to Answer". All AE fields apply to ZOSTAVAX; no dose of VARIVAX was administered. No additional information is available. Additional information is not expected.
Sex: F
Vaccine: MMR
Symptoms: Rubella antibody negative
Clinical narrative: This spontaneous report was received from a nurse referring to a 55-year-old female patient. The patient's pertinent medical history, concurrent conditions, and concomitant medications were unknown by the reporter. The patient did not have drug reactions/allergies. On an unknown date (as a child), the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) for prophylaxis (dose, frequency, route of administration, lot number and expiration date were not reported). On an unknown date, the patient went to the office for required vaccinations to operate a day care center. The reporter stated that a serology testing was conducted in March 2017 (one or two weeks ago), to detect immunity and the result was reported as measles and mumps were acceptable; but rubella was indeterminate, like less than 90, inconsistent with immunity (rubella antibody negative). No treatment was given for the adverse events. The reporter stated she did not have the whole report available, therefore, some information was not known. At the time of the report, the patient was "pretty healthy". No further information was provided. The outcome of the event rubella antibody negative and the causal relationship between the event and therapy with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) were not reported. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Expired product administered, No adverse event
Clinical narrative: This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patient was vaccinated with the expired dose of PNEUMOVAX23 (dose, route of administration, lot # and expiration date were not reported) for prophylaxis. No adverse effects were reported. Additional information has been requested.
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4 year-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 25-OCT-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 1.33
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 16 month-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 26-OCT-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX) lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509:US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4 year-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 26-OCT-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.
Age: 1.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 12 month-old patient of unknown gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history reported. On 26-OCT-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with an expiration date on 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. No data logger was involved. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 1.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 12 months old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 22-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested. Sender's Comments: US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004498: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515:  US-009507513-1704USA004516: US-009507513-1704USA004517.
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4-year-old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 29-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004499: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517:
Age: 4.0
Sex: U
Vaccine: VARCEL
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: This spontaneous report was received from an office manager and refers to a 4-year-old patient of unknown gender. There was no information about patient's concomitant medications and pertinent medical history reported. On 30-NOV-2016, the patient was vaccinated with the first improperly stored dose of VARIVAX, lot number M027885 with expiration date 30-JUN-2018 (dose, route and anatomical location was not reported) for prophylaxis. The vaccine was exposed to temperature of 7.7 Fahrenheit (F) during 24 hours. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1612USA007652: US-009507513-1704USA004460: US-009507513-1704USA004461: US-009507513-1704USA004462: US-009507513-1704USA004463: US-009507513-1704USA004464: US-009507513-1704USA004465: US-009507513-1704USA004466: US-009507513-1704USA004467: US-009507513-1704USA004468: US-009507513-1704USA004469: US-009507513-1704USA004470: US-009507513-1704USA004471: US-009507513-1704USA004472: US-009507513-1704USA004473: US-009507513-1704USA004474: US-009507513-1704USA004475: US-009507513-1704USA004476: US-009507513-1704USA004477: US-009507513-1704USA004478: US-009507513-1704USA004479: US-009507513-1704USA004480: US-009507513-1704USA004481: US-009507513-1704USA004482: US-009507513-1704USA004483: US-009507513-1704USA004484: US-009507513-1704USA004485: US-009507513-1704USA004486: US-009507513-1704USA004487: US-009507513-1704USA004488: US-009507513-1704USA004489: US-009507513-1704USA004490: US-009507513-1704USA004491: US-009507513-1704USA004492: US-009507513-1704USA004493: US-009507513-1704USA004494: US-009507513-1704USA004495: US-009507513-1704USA004496: US-009507513-1704USA004497: US-009507513-1704USA004498: US-009507513-1704USA004500: US-009507513-1704USA004501: US-009507513-1704USA004502: US-009507513-1704USA004503: US-009507513-1704USA004504: US-009507513-1704USA004505: US-009507513-1704USA004506: US-009507513-1704USA004507: US-009507513-1704USA004508: US-009507513-1704USA004509: US-009507513-1704USA004510: US-009507513-1704USA004511: US-009507513-1704USA004512: US-009507513-1704USA004513: US-009507513-1704USA004514: US-009507513-1704USA004515: US-009507513-1704USA004516: US-009507513-1704USA004517: